申请人:Joel Simon Peter
公开号:US20100160392A1
公开(公告)日:2010-06-24
The present invention provides histone deacetylase inhibitors of general formula (I), a process for the preparation of such compounds and uses of the compounds in medicine, especially in the treatment of cancers: in which R
1
is an optionally substituted aryl, arylalkyl, heteroaryl, heterocycloalkenyl, cycloalkene ring, cycloalkyl, heterocycloalkyl or a combination of such rings to form a linked or fused ring system, R
2
and R
3
is each independently hydrogen, optionally substituted saturated or unsaturated alkyl, optionally substituted aryl or heteroaryl, or a combination thereof to form a linked or fused ring system, alkoxy, thioalkoxy, hydroxyl, hydroxyalkyl, halo, haloalkyl, cyano, nitro, amino, amido, alkylamino, alkylcarbonyloxy, alkoxycarbonyl, alkylcarbonyl, alkylthiocarbonyl, alkylsulfonylamino, aminosulfonyl, alkylsulfinyl, or alkylsulfonyl, or R
3
is absent when Y stands for O or S, or R
2
and R
3
may be linked together and such that, together with the intervening atoms, they form a 5, 6 or 7-membered ring containing one or more heteroatoms, which may be a heteroaryl ring, heterocycloalkenyl ring, or heterocycloalkyl ring, optionally containing up to 4 heteroatoms, e.g. oxygen, nitrogen or sulphur, which ring may be fused to further rings as part of a fused ring system, and which may bear 1, 2 or 3 substituents, which substituents independently have the same meaning as R
2
on any or all of those rings, Q stands for an (alkyl, which may be unsaturated; aryl, arylalkyl, alkylaryl or alkylarylalkyl, all of which may be optionally substituted; and may be optionally interrupted by O, S, NR, CO, C(N═R), where R may be independently hydrogen, alkyl, alkenyl, alkynyl, or alkoxy; V is OH, SH, SR, OR, NH2, NHR, NRR, NROH, NHOR, NROR where R may independently be hydrogen or (C
1
-C
6
) alkyl, Y is oxygen, or sulphur or N, and Z is O, S, S(═O), S(O)2, NR
4
, —N═, CR
4
R
5
, or —C(R4)=, where R
4
and R
5
independently have the same meaning as R
2
.
本发明提供了通式(I)的组蛋白去乙酰化酶抑制剂,以及制备这些化合物的方法和在医学中使用这些化合物,特别是在癌症治疗中的用途:其中R1是可选取代的芳基,芳基烷基,杂芳基,杂环烯烃基,环烯烃基,环烷基,杂环烷基或这些环的组合,形成连接或融合的环系统,R2和R3各自独立地是氢,可选取代的饱和或不饱和烷基,可选取代的芳基或杂芳基,或它们的组合以形成连接或融合的环系统,烷氧基,硫代烷氧基,羟基,羟基烷基,卤素,卤素烷基,氰基,硝基,氨基,酰胺基,烷基氨基,烷基羰氧基,烷氧羰基,烷基羰基,烷硫酰氨基,氨基磺酰基,烷基亚磺酰基或烷基磺酰基,或当Y代表O或S时,R3不存在,或R2和R3可以连接在一起,使它们与介入原子一起形成一个含有一个或多个杂原子的5、6或7元环,其中可能是杂芳基环,杂环烯烃基环或杂环烷基环,可选包含高达4个杂原子,例如氧,氮或硫,该环可以与进一步的环融合成为融合环系统的一部分,并且可以带有1、2或3个取代基,这些取代基独立地具有与R2在这些环上任何或所有环上相同的含义,Q代表(烷基,可以是不饱和的;芳基,芳基烷基,烷基芳基或烷基芳基烷基,所有这些都可以是可选的取代基;并且可以通过O,S,NR,CO,C(N═R)中断,其中R可以独立地是氢,烷基,烯基,炔基或烷氧基;V是OH,SH,SR,OR,NH2,NHR,NRR,NROH,NHOR,NROR,其中R可以独立地是氢或(C1-C6)烷基,Y是氧,硫或N,Z是O,S,S(═O),S(O)2,NR4,—N═,CR4R5或—C(R4)=,其中R4和R5独立地具有与R2相同的含义。